CORT stock forecast, quote, news & analysis
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone... Show more
Why Corcept Therapeutics (CORT) Is Up +32% in the Last 30 Days
Key Takeaways
- Corcept Therapeutics (CORT) stock surged +32% over the past 30 days, primarily driven by the FDA (U.S. Food and Drug Administration) approval of its new drug Lifyorli for ovarian cancer.
- The stock rose +27% over the past quarter, reflecting recovery from earlier earnings disappointment and growing optimism around pipeline expansion.
- Key catalysts include Lifyorli's first-in-class status, insider buying, and sustained Korlym revenue growth despite Q4 earnings miss.
- Market sentiment shifted positively amid biopharma sector trends and analyst upside targets around $67.
- Fundamentals show profitability with trailing EPS (earnings per share) of $0.82 and revenue of $761 million TTM (trailing twelve months).
Corcept Therapeutics (CORT) Company Overview and Market Position
Corcept Therapeutics Incorporated (CORT) is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing drugs that modulate cortisol activity to treat severe disorders in endocrinology, oncology, metabolism, and neurology. Its flagship product, Korlym (mifepristone), treats endogenous Cushing's syndrome by antagonizing the glucocorticoid receptor. The company generates revenue primarily from Korlym sales while advancing a pipeline including relacorilant (branded as Lifyorli). In the competitive biopharma landscape, Corcept holds a niche position in cortisol modulation therapies, with limited direct rivals. Strong cash reserves of $372 million and low debt support R&D (research and development), explaining resilience amid stock volatility and recent upside from pipeline milestones.
Corcept Therapeutics (CORT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CORT stock climbed from a closing price of $33.30 on March 18 to $43.96 on April 16, marking a +32% gain. The movement was volatile but trend-driven, with a sharp surge post-FDA approval followed by steady gains.
In the past quarter, shares advanced from $34.73 on January 16 to $43.96, delivering a +27% return. Performance was range-bound early before accelerating upward, reflecting improved investor confidence. The stock traded within a 52-week range of $28.66 to $91.00, underscoring its sensitivity to news.
What Drove CORT Stock Price in the Last 30 Days
The primary catalyst was the FDA's approval of Lifyorli (relacorilant) on March 25 in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer—the first selective glucocorticoid receptor modulator approved for this indication. Shares surged nearly 20% immediately following the announcement, boosting market cap and drawing analyst attention.
An insider purchase of 100,000 shares by a director on March 17 at around $33 further signaled confidence, coinciding with the pre-approval rally. Positive sector sentiment in oncology biopharma, coupled with Korlym's steady sales, amplified the upward momentum. No major downgrades occurred, sustaining the price movement.
What Drove CORT Stock Performance Over the Last Quarter
The quarter's +27% gain stemmed from post-earnings recovery after Q4 2025 results on February 24, where EPS of $0.20 missed estimates of $0.27, but revenues rose 11% year-over-year to contribute to full-year growth. Guidance for 2026 revenues of $900 million to $1 billion reassured investors despite the miss.
Building anticipation for Lifyorli approval dominated the narrative, alongside Korlym's market position amid ongoing patent litigation. Broader biopharma trends, including oncology demand and favorable macro conditions like stable interest rates, supported accumulation. Institutional interest grew, with low beta (0.25) indicating defensive positioning relative to peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum trading, across short-term, swing, or long-term timeframes. Performance metrics like win rate, average return, and Sharpe ratio highlight their edge, with filters for relevance to specific stocks like CORT or sectors like biopharma. Updated in real-time, the section helps investors discover bots aligned with current market trends or personalized portfolios. Explore Trending AI Robots to integrate cutting-edge automation into your stock analysis and trading strategy.
CORT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Q1 2026 earnings for Korlym sales trends and Lifyorli launch progress, including initial uptake and reimbursement details. Pipeline updates on relacorilant in other indications, such as Cushing's monotherapy, could influence sentiment. Industry developments in oncology and endocrinology, including competitive therapies, remain key. Macro factors like healthcare policy changes or interest rates may impact biopharma valuations. Risks include patent challenges for Korlym and commercialization hurdles for new drugs, alongside general market volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
CORT in +0.97% Uptrend, rising for three consecutive days on June 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CORT advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In of 244 cases where CORT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CORT moved out of overbought territory on June 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CORT broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.441) is normal, around the industry mean (20.059). CORT has a moderately high P/E Ratio (228.314) as compared to the industry average of (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). CORT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (12.063) is also within normal values, averaging (361.315).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drugs for the treatment of severe psychiatric and neurological diseases
Industry Biotechnology